ObjectiveTo study the effects and mechanism of Octreotide to inhibit the proliferation of human gastric cancer cells in vitro. MethodsHuman gastric cancer cell line SGC7901 was treated with Octreotide. Human fibroblast cell line HF and 5FU were used as control. MTT assay and fluorescent microscopy as well as flow cytometry were performed in this study. ResultsOctreotide inhibited the growth of SGC7901 in vitro within certain concentrations. The suppression was quantity dependent but did not occur when up to a certain concentration. There was no difference between Octreotide and 5FU in their inhibition on SGC7901. Octreotide had no effects on normal human fibroblast cell line HF. When SGC7901 was treated with Octreotide, the typical apoptotic bodies were identified by flow cytometry and fluorescent microscopy. ConclusionOctreotide can inhibit the proliferation of human gastric cancer cell line SGC7901 in vitro. The induction of apoptosis by Octreotide might be the primary mechanism.
Citation：
L Wencai,GENG Xiaoping,MENG Xiangling,TAN Wenxiang. ApoptosisInduction Effects of Octreotide on Human Gastric Cancer Cells. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(3): 238-241. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [Ｊ]. Cancer, 1995; 76(6)∶ 961.
|
| 2. |
Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [Ｊ]. Am J Gastroenterol， 1998; 93(9)∶1468.
|
| 3. |
Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [Ｊ]. Ann Oncol， 1997; 8(10)∶1041.
|
| 4. |
Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [Ｊ]. Rev Med Interne， 1999; 20(5)∶421.
|
| 5. |
郑永唐，贲昆龙. 测定细胞存活和增殖的MTT方法的建立 [Ｊ]. 免疫学杂志， 1992； 8（4）∶266.
|
| 6. |
Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [Ｊ]. Gut， 1996; 38(3)∶430.
|
| 7. |
Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [Ｊ]. Digestion， 1999; 60（Suppl 2）∶9.
|
| 8. |
鄂征主编. 组织培养和分子细胞学技术 [M]. 第1版. 北京： 北京出版社， 1995∶203～205.
|
| 9. |
Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [Ｊ]. Cancer, 1996; 78(1)∶35.
|
| 10. |
Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [Ｊ]. Cancer Res, 1998; 58(11)∶2375.
|
| 11. |
Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [Ｊ]. Int J Cancer, 1995; 60(5)∶694.
|
| 12. |
Reisine T. Somatostatin receptors [Ｊ]. Am J Physiol， 1995; 269(6 Pt 1)∶G813.
|
| 13. |
吴苏冬， 刘长利， 王慧川， 等. 参臼胶囊诱导肝癌SMMC7721细胞凋亡 [Ｊ]. 世界华人消化杂志， 2003； 11（7）∶908.
|
- 1. Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [Ｊ]. Cancer, 1995; 76(6)∶ 961.
- 2. Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [Ｊ]. Am J Gastroenterol， 1998; 93(9)∶1468.
- 3. Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [Ｊ]. Ann Oncol， 1997; 8(10)∶1041.
- 4. Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [Ｊ]. Rev Med Interne， 1999; 20(5)∶421.
- 5. 郑永唐，贲昆龙. 测定细胞存活和增殖的MTT方法的建立 [Ｊ]. 免疫学杂志， 1992； 8（4）∶266.
- 6. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [Ｊ]. Gut， 1996; 38(3)∶430.
- 7. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [Ｊ]. Digestion， 1999; 60（Suppl 2）∶9.
- 8. 鄂征主编. 组织培养和分子细胞学技术 [M]. 第1版. 北京： 北京出版社， 1995∶203～205.
- 9. Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [Ｊ]. Cancer, 1996; 78(1)∶35.
- 10. Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [Ｊ]. Cancer Res, 1998; 58(11)∶2375.
- 11. Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [Ｊ]. Int J Cancer, 1995; 60(5)∶694.
- 12. Reisine T. Somatostatin receptors [Ｊ]. Am J Physiol， 1995; 269(6 Pt 1)∶G813.
- 13. 吴苏冬， 刘长利， 王慧川， 等. 参臼胶囊诱导肝癌SMMC7721细胞凋亡 [Ｊ]. 世界华人消化杂志， 2003； 11（7）∶908.
